相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。METABOLISM Structural basis for leucine sensing by the Sestrin2-mTORC1 pathway
Robert A. Saxton et al.
SCIENCE (2016)
METABOLISM Sestrin2 is a leucine sensor for the mTORC1 pathway
Rachel L. Wolfson et al.
SCIENCE (2016)
EGFR gene deregulation mechanisms in lung adenocarcinoma: A molecular review
Evangelos Tsiambas et al.
PATHOLOGY RESEARCH AND PRACTICE (2016)
Sestrin regulation of TORC1: Is Sestrin a leucine sensor?
Jun Hee Lee et al.
SCIENCE SIGNALING (2016)
EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?
E-E Ke et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Sestrin regulation of TORC1: Is Sestrin a leucine sensor?
Jun Hee Lee et al.
SCIENCE SIGNALING (2016)
Dietary agents for prevention and treatment of lung cancer
Naghma Khan et al.
CANCER LETTERS (2015)
The potential of sestrins as therapeutic targets for diabetes
Xiaocheng Charlie Dong
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
Sestrin 3 Protein Enhances Hepatic Insulin Sensitivity by Direct Activation of the mTORC2-Akt Signaling
Rongya Tao et al.
DIABETES (2015)
Quercetin Down-regulates IL-6/STAT-3 Signals to Induce Mitochondrial-mediated Apoptosis in a Non-small-cell Lung-cancer Cell Line, A549
Avinaba Mukherjee et al.
JOURNAL OF PHARMACOPUNCTURE (2015)
Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
Ho-June Lee et al.
CANCER CELL (2014)
Inhibition of HER2-integrin signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression
Parul Gupta et al.
ONCOTARGET (2014)
mTOR direct interactions with Rheb-GTPase and raptor: sub-cellular localization using fluorescence lifetime imaging
Rahul B. Yadav et al.
BMC CELL BIOLOGY (2013)
Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
Qingsong Liu et al.
CANCER RESEARCH (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer
Ahmed Aribi et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival
W. N. William et al.
ANNALS OF ONCOLOGY (2012)
Maintenance of Metabolic Homeostasis by Sestrin2 and Sestrin3
Jun Hee Lee et al.
CELL METABOLISM (2012)
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non-Small-Cell Lung Cancer
Vassiliki Papadimitrakopoulou
JOURNAL OF THORACIC ONCOLOGY (2012)
Signaling Networks Associated with AKT Activation in Non-Small Cell Lung Cancer (NSCLC): New Insights on the Role of Phosphatydil-Inositol-3 kinase
Marianna Scrima et al.
PLOS ONE (2012)
Cucurbitacin B Causes Increased Radiation Sensitivity of Human Breast Cancer Cells via G2/M Cell Cycle Arrest
Suwit Duangmano et al.
JOURNAL OF ONCOLOGY (2012)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer
Gabriela B. Iwanski et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Christine M. Chresta et al.
CANCER RESEARCH (2010)
mTOR and cancer: many loops in one pathway
Alejo Efeyan et al.
CURRENT OPINION IN CELL BIOLOGY (2010)
The PKB/AKT Pathway in Cancer
Amancio Carnero
CURRENT PHARMACEUTICAL DESIGN (2010)
FoxOs Inhibit mTORC1 and Activate Akt by Inducing the Expression of Sestrin3 and Rictor
Chia-Chen Chen et al.
DEVELOPMENTAL CELL (2010)
Stressin' Sestrins take an aging fight
Andrei V. Budanou et al.
EMBO MOLECULAR MEDICINE (2010)
Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies
N. Chapuis et al.
LEUKEMIA (2010)
Sestrin as a Feedback Inhibitor of TOR That Prevents Age-Related Pathologies
Jun Hee Lee et al.
SCIENCE (2010)
Targeted constitutive activation of signal transducer and activator of transcription 3 in human hepatocellular carcinoma cells by cucurbitacin B
Meixia Zhang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non-Small Cell Lung Cancer Harboring K-RAS Mutations
Georgia Konstantinidou et al.
CANCER RESEARCH (2009)
Cucurbitacin B Induces Apoptosis by Inhibition of the JAK/STAT Pathway and Potentiates Antiproliferative Effects of Gemcitabine on Pancreatic Cancer Cells
Nils H. Thoennissen et al.
CANCER RESEARCH (2009)
Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer
Amy Kluge et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Class IA Phosphatidylinositol 3-Kinase Signaling in Non-small Cell Lung Cancer
Benjamin Solomon et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
p53 target genes Sestrin1 and Sestrin2 connect genotoxic stress and mTOR signaling
Andrei V. Budanov et al.
CELL (2008)
AMPK phosphorylation of raptor mediates a metabolic checkpoint
Dana M. Gwinn et al.
MOLECULAR CELL (2008)
Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells
Talin Haritunians et al.
LEUKEMIA RESEARCH (2008)
AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy
D. Grahame Hardie
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Targeting mTOR signaling in lung cancer
Marin Marinov et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Apoptosis by dietary factors: the suicide solution for delaying cancer growth
Naghma Khan et al.
CARCINOGENESIS (2007)
Current development of mTOR inhibitors as anticancer agents
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Molecular context of the EGFR mutations:: Evidence for the activation of mTOR/S6K signaling
E Conde et al.
CLINICAL CANCER RESEARCH (2006)
Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer
EB Haura et al.
CLINICAL CANCER RESEARCH (2005)
Cucurbitacins and cucurbitane glycosides: structures and biological activities
JC Chen et al.
NATURAL PRODUCT REPORTS (2005)
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions
BR Balsara et al.
CARCINOGENESIS (2004)
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
E Jacinto et al.
NATURE CELL BIOLOGY (2004)
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells
LX Song et al.
ONCOGENE (2003)
PA26 is a candidate gene for heterotaxia in humans:: identification of a novel PA26-related gene family in human and mouse
H Peeters et al.
HUMAN GENETICS (2003)
Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation
K Kato et al.
ONCOGENE (2002)
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control
R Loewith et al.
MOLECULAR CELL (2002)
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action
K Hara et al.
CELL (2002)
MTOR interacts with Raptor to form a nutrient-sensitive complex that signals to the cell growth machinery
DH Kim et al.
CELL (2002)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival
S Grant et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2002)
TOR, a central controller of cell growth
T Schmelzle et al.
CELL (2000)
分享论文
